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Protocol
AbstrACt
Introduction The current evidence for the prevention of 
saphenous vein graft failure (SVGF) after coronary artery 
bypass graft (CABG) surgery consists of direct head-to-
head comparison of treatments (including placebo) in 
randomised-controlled trials (RCTs) and observational 
studies. However, summarising the evidence using 
traditional pairwise meta-analyses does not allow the 
inclusion of data from treatments that have not been 
compared head to head. Exclusion of such comparisons 
could impact the precision of pooled estimates in a meta-
analysis. Hence, to address the challenge of whether 
aspirin alone or in addition to another antithrombotic agent 
is a more effective regimen to improve SVG patency, a 
network meta-analysis (NMA) is necessary. The objectives 
of this study are to synthesise the available evidence on 
antithrombotic agents (or their combination) and estimate 
the treatment effects among direct and indirect treatment 
comparisons on SVGF and major adverse cardiovascular 
events, and to generate a treatment ranking according to 
their efficacy and safety outcomes. 
Methods We will perform a systematic review of RCTs 
evaluating antithrombotic agents in patients undergoing 
CABG. A comprehensive English literature search will be 
conducted using electronic databases and grey literature 
resources to identify published and unpublished articles. 
Two individuals will independently and in duplicate screen 
potential studies, assess the eligibility of potential studies 
and extract data. Risk of bias and quality of evidence will 
also be evaluated independently and in duplicate. We 
will investigate the data to ensure its suitability for NMA, 
including adequacy of the outcome data and transitivity of 
treatment effects. We plan to estimate the pooled direct, 
indirect and the mixed effects for all antithrombotic agents 
using a NMA.
Ethics and dissemination Due to the nature of the 
study, there are no ethical concerns nor informed consent 
required. We anticipate that this NMA will be the first to 
simultaneously assess the relative effects of multiple 
antithrombotic agents in patients undergoing CABG. 
The results of this NMA will inform clinicians, patients 
and guideline developers the best available evidence on 
comparative effects benefits of antithrombotic agents after 
CABG while considering the side effect profile to support 
future clinical decision-making. We will disseminate the 
results of our systematic review and NMA through a peer-
reviewed journal.
PrOsPErO registration number CRD42017065678.
IntrOduCtIOn
Despite the remarkable advance in percu-
taneous coronary intervention (PCI) and 
drug-eluting stents, coronary artery bypass 
grafting (CABG) is still the preferred treat-
ment for patients presenting with multivessel 
coronary artery disease.1 2 However, CABG 
patients remain at risk for subsequent major 
adverse cardiovascular events (MACE) and 
saphenous vein graft failure (SVGF).3–5 SVGs 
are the most commonly used conduits and 
previous studies reported that 15% to 30% 
of SVGs occlude within the first year after 
CABG6 and approximately 40% to 60% at 10 
years after surgery.7–9
The use of acetylsalicylic acid (aspirin) 
has been associated with improved 
strengths and limitations of this study
 ► This review is anticipated to be the first network me-
ta-analysis to evaluate the comparative effects of 
multiple antithrombotic agents in patients undergo-
ing coronary artery bypass graft.
 ► The strengths of this review are the comprehensive 
literature search strategy, restriction of studies to 
randomised controlled trials, duplicate assess-
ment of eligibility, risk of bias and data abstraction. 
We will also use the Grade of Recommendations 
Assessment, Development and Evaluation system to 
rate the quality of evidence.
 ► This study will be limited to trials that assessed the 
effects of antithrombotic agents on saphenous vein 
graft failure. A high rate of loss to follow-up is there-
fore expected.
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clinical outcomes and reduction in SVGF after CABG 
surgery.1 2 10–17 Antiplatelet agents other than aspirin (ie, 
clopidogrel) have been reported as an alternative option, 
although with conflicting efficacy in the literature.18–22 In 
addition, medications that inhibit venous thrombi forma-
tion, such as oral anticoagulants (OAC), have also been 
tested in clinical trials to provide protection against SVGF 
but with an increased risk of bleeding as a trade-off.17 23
Thus far, the evidence for the prevention of SVGF 
consists of direct head-to-head comparison of treatments 
(including placebo) in randomised-controlled trials 
(RCTs) and observational studies. This poses a practical 
challenge to clinicians for choosing therapeutic alterna-
tives because a direct comparison is rarely seen or not 
available for many antithrombotic agents. In addition, 
summarising evidence using the traditional pairwise 
meta-analyses would not allow for the inclusion of data 
from treatments that have not been compared head-to-
head and thus, the results from indirect combined with 
direct evidence can improve precision for treatments 
that have been directly evaluated.24 Therefore, to address 
the challenge of whether aspirin alone, or in addition to 
another antithrombotic agent is a more effective regimen 
to improve SVG patency, a network meta-analysis (NMA) 
is necessary. Hence, the objectives of this study are to 
synthesise the available evidence on antithrombotic 
agents (or their combination) and estimate the treatment 
effects among direct and indirect treatment comparisons 
on SVGF and MACE, and to generate a treatment ranking 
according to their efficacy and safety outcomes using a 
NMA.
MEthOds And dEsIgn
This systematic review will be conducted according 
to the Cochrane Collaboration recommendations,25 
and will adhere to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) Exten-
sion for NMAs of healthcare interventions guidelines 
(online supplementary material).26 Our systematic review 
and NMA protocol has been registered in the Interna-
tional Prospective Register for Systematic Reviews (PROS-
PERO: CRD42017065678).
Eligibility criteria
The eligibility criteria are pre-specified according to the 
PICO(S) criteria.
Types of participants
Participants will include adults≥18 years undergoing 
CABG surgery and receiving at least one SVG. To increase 
the likelihood of transitivity assumption being met, we will 
exclude studies that included participants with clinical 
conditions that prevent them from receiving one or more 
of the above treatments. For example, we will exclude 
studies including participants with thromboembolic 
disease or undergoing concomitant mechanical valve 
replacement needing life-long OAC, or those comparing 
clopidogrel to placebo in patients with a contraindica-
tion for aspirin (ie, allergy) or warfarin (ie, prior major 
bleeding).
Types of interventions
The interventions are aspirin, clopidogrel, prasugrel, tica-
grelor, vitamin K antagonists (warfarin, acenocoumarol 
or phenprocoumon), new OAC (rivaroxaban, apixaban, 
dabigatran) and placebo, regardless of drug regimen. 
We will assess the comparability of any other antithrom-
botic agents that we are not aware of, with those stated 
above, and then will consider them eligible if they are still 
used in clinical practice. The comparator can be placebo, 
inactive control or a different oral antithrombotic agent. 
Comparing interventions of the same drug with different 
regimens is beyond the scope of this study.
Types of outcome
Included studies must report SVGF as one of the 
endpoints (defined below).
 ► Primary outcome: SVGF as per-patient analysis;
 ► Secondary efficacy outcomes: all-cause mortality, any 
stroke (ischaemic or haemorrhagic) or transient 
ischaemic attack, any myocardial infarction (fatal or 
non-fatal) and major bleeding;
 ► Secondary safety outcomes: intracranial haemor-
rhage, life-threatening bleeding, minor bleeding, red 
blood cells transfusion, MACE and hospital readmis-
sion due to cardiovascular cause.
We anticipate study authors will use a variety of defi-
nitions for bleeding and for SVGF. If several definitions 
of major bleeding are presented in the same study, our 
preferred definition will be according to the Thrombolysis 
In Myocardial Infarction criteria.27 Our preferred defini-
tion for SVGF will be total occlusion (100%) as detected 
by invasive angiography or non-invasive CT assessment on 
a per-patient basis (ie, patients with at least one occluded 
SVG). If the study does not provide data corresponding 
to the preferred definition of SVGF, we will incorporate 
study data reported in the following way, based on this 
priority sequence:
 ► Any SVG stenosis deemed to require treatment with 
PCI on a per-patient basis;
 ► Cardiac reintervention (defined as the need for 
SVG-related PCI or repeat CABG);
 ► SVG stenosis >70% on a per-patient basis;
 ► SVG stenosis >70% on a per-graft basis;
 ► Any SVG stenosis deemed to be treated with PCI on a 
per-graft basis.
In addition, when available, data on perioperative 
SVGF will be excluded from the analysis as such SVGF 
occurs mainly due to technical factors (eg, mechanical 
trauma, poor distal run-off), regardless of the interven-
tion received, resulting in underestimation of the results. 
The remaining outcomes will be defined per study author 
definition. Finally, and based on available data, we will 
categorise outcomes on reported timelines of follow-up 
as short, medium and long term.
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Types of studies
Eligible studies are RCTs assessing the effect of oral anti-
thrombotic agents on SVGF after CABG.
search strategy
A comprehensive search in English literature will be 
conducted using the following electronic databases: 
Medline, Embase, Web of Science, Cumulative Index 
of Nursing and Allied Health and Cochrane Library to 
identify published articles on antithrombotic therapy 
following CABG, from inception to November 2017. In 
consultation with a medical librarian, the search strategy 
will be created to combine relevant Medical Subject Head-
ings (MeSH) and keywords with synonyms and names of 
generic and brand names of the antithrombotic agents. 
The search will not be restricted by year of publication. 
Additionally, we will perform a grey literature search using 
trial registries (eg,  ClinicalTrials. gov), regulatory agency 
databases, drug companies, dissertations and conference 
proceedings for unpublished studies. We will also check 
reference lists of included RCTs and relevant systematic 
reviews. Monthly search alerts will be set up for electronic 
databases to identify any new published articles until the 
submission of the present study. Contact with experts 
in the field of interest will also be sought to inquire 
about unpublished studies. A detailed search strategy 
for all databases including search concepts, MeSH term, 
keywords and Boolean operators is presented within the 
online supplementary material. Non-English language 
studies and ongoing RCTs without extractable data will 
be excluded. Duplicate publications of original research 
will be also excluded. If the same population was used in 
multiple studies, the article with the longest follow-up will 
be included.
study selection
To assess study eligibility, all title/abstracts and full-text 
articles will be independently screened by two reviewers 
and disagreements will be resolved by a third reviewer. 
If necessary, methodological experts will be consulted 
to reach consensus. Eligible articles will be selected 
according to prespecified inclusion criteria and the selec-
tion process is shown in online supplementary figure 1.
data extraction
The study data will be extracted independently and in 
duplicate from eligible studies and will include study and 
publication details, participants and intervention char-
acteristics as well as outcome data (table 1). Whenever 
possible, we will extract arm-level data (ie, number of 
events) from the included studies, otherwise, contrast-
level data (ie, effect sizes and standard errors of a direct 
comparison) will be used. The study data will be collected 
using a predetermined data collection template, which 
will be pilot tested on a few randomly- elected included 
studies. In case of insufficient information, the study 
authors will be contacted to provide further informa-
tion. Two independent reviewers will perform data 
extraction and in case of discrepancies, a third reviewer 
will be consulted. We will extract arm-level data whenever 
possible.
risk of bias assessment
Risk of bias in the eligible trials will be assessed using 
the updated Cochrane Collaboration Risk of Bias Tool 
(RoB V.2.0),28 which consists of five domains of bias that 
are relevant to the quality of RCTs. The five domains 
include bias due to the randomisation process, deviation 
from intended intervention, incomplete outcome data, 
measurement of the outcome, and selective reporting. 
Table 1 Data extraction template
Publication details
First author, country of conduct, funding sources (for profit, mixed and non-profit) and year of 
publication.
Study
characteristics
Study design (randomised or non-randomised), setting (single or multicentre), accrual period, 
length of follow-up, inclusion and exclusion criteria, Cochrane risk of bias, rates of loss to follow-
up (with reasons), number of study arms, number of patients randomised per arm, number of 
patients analysed per arm, antifibrinolytic use during surgery (eg, aprotinin or tranexamic acid) 
and surgical technique (eg, endarterectomy or not, off pump or on pump, endoscopic vein 
harvesting or open harvesting, single or multiple vein grafts, sequential grafts, ‘no-touch’ grafting 
or conventional)
Participant characteristics Age; proportion of women; proportion of patients with atrial fibrillation or flutter, hyperlipidaemia, 
prior MI, prior TIA/stroke, heart failure (NYHA functional class III–IV), diabetes mellitus, 
hypertension or chronic kidney disease; number of vessel grafted, left ventricular ejection fraction
Intervention characteristics Dose, frequency, duration, timing for the start of treatment and adherence
Outcomes of Interest Number of patients with SVGF, major bleeding, any stroke or TIA, any MI, heart failure, intracranial 
haemorrhage; number patients needed RBCs transfusions; number of patients admitted to 
hospital due to cardiovascular cause; number of deaths; number of occluded SVGs; authors’ 
definitions of outcomes; time and method for outcome assessments and any subgroup analyses
MI, myocardial infarction; NYHA, New York Heart Association; RBCs, red blood cells; SVGF, saphenous vein graft failure; TIA, transient 
ischaemic attack.
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Each domain will be assigned a score of 'high risk' 
(if the study is at high risk of bias for more than one 
domain or some concerns for multiple domains), ‘low 
risk’ (if the study is at low risk of bias for all domains) 
or ‘some concern’ (if the study has some concern for at 
least one domain) depending on the degree of bias on an 
outcome level.
rating the confidence in estimates of the effect in the network 
meta-analysis
Once the NMA is completed, we will then appraise the 
quality of treatment effect estimates using the Grade of 
Recommendations Assessment, Development and Eval-
uation (GRADE) working group for NMA.29 We will 
follow the four-step approach29: once we obtain direct 
and indirect treatment estimates, we will rate the quality 
of evidence from the direct and indirect comparisons 
using the five GRADE categories: risk of bias, inconsis-
tency, indirectness, imprecision and publication bias. We 
will then rate the quality of evidence of the NMA effect 
estimate.
Measures of treatment effect
The primary unit of analysis will be based on per-patient 
outcomes measures. If per-patient data were not available 
in all included studies, the unit of analysis will depend on 
the consistency of the results (magnitude and direction of 
effect estimates) between the per-patient versus per-graft 
meta-analysis for all direct treatment comparisons. If 
these meta analyses yield different effects, we will conduct 
a separate analysis for each level; however, if there is no 
important difference in effect sizes (ie, large overlaps in 
the 95% CI of effect sizes) between units of analysis for all 
comparisons, we will pool data from studies that reported 
the per-patient data with those that reported only the 
per-graft data (accounting for clustering effects). We will 
then report results generating an inference at patient-
level analysis as it is clinically relevant to apply the inter-
vention to the patient.
Methods for indirect and mixed comparisons
We will present indirect comparisons of antithrombotic 
agents using a network diagram for outcomes that have 
at least 10 studies. If there are any trials that formed a 
node, which are not connected to the rest of the network, 
we will exclude them. The common comparator will be 
aspirin as it is the current standard of care.1 2 17 To assess 
whether the transitivity assumption (ie, the distribution 
of treatment response is similar across all RCTs) holds, 
we will qualitatively assess the distribution of patient and 
study characteristics that modify treatment effects (ie, 
effect modifiers; see subgroup analysis and metaregres-
sion) across treatment comparisons by presenting tabu-
lated results of these characteristics. We will also evaluate 
the statistical manifestation of the assumption, known as 
consistency assumption by performing a global test for 
inconsistency (design-by-treatment interaction model)30 
and a local test (inconsistency plot)31 to identify sources 
of inconsistency within every closed loop in the network. 
In case the transitivity assumption is violated, methods for 
covariate adjustment will be considered.32 33
The NMA will be based on a mixed treatment compar-
ison model generation using the network commands 
package (Stata V.14.0, StataCorp).34 We will conduct 
a frequentist hierarchical random-effects model for 
conducting our NMA. The OR will be reported along 
with 95% CIs. A network diagram will be generated to 
show the size of the different trials and the weight that 
it contributes towards the point estimate. P<0.05 will be 
considered statistically significant.
Treatment ranking
To estimate the percentage of efficacy of each antithrom-
botic agent for being at each possible rank, we will use the 
surface under the cumulative ranking curve (SUCRA).31 35 
The higher the SUCRA score, the more efficacious the 
treatment is expected to be.
Studies with multiple treatment groups
Multiarm studies will be included and will be treated 
as multiple independent two-arm studies in pair-
wise meta-analyses. In the NMA, we will include such 
studies and account for the correlations between effect 
sizes induced by multiarm studies using a multivariate 
approach.36
dealing with missing data
We will attempt to contact study authors to obtain missing 
data. We will also discuss reasons for missing data as well 
as its extent and nature and how missing data was handled 
by each study. We will conduct sensitivity analyses, such 
as best-worst case scenario analysis for dichotomous 
outcome, to explore the potential impact of the missing 
data. Since we anticipate that some patients will be lost to 
follow-up, and some studies will ascertain angiographic 
follow-up on only a subset of the whole population, we 
will also record the ‘loss to follow-up’ to inform sensitivity 
analyses using different assumptions about the missing 
data (see sensitivity analysis). We will extract data from 
studies that report outcomes using the intention-to-treat 
principle, that is, we will analyse all participants according 
to the treatment they were randomised to, as long as the 
deviation from the protocol is negligible.
Assessment of reporting bias
When a sufficient number of studies is available (at least 
10 trials) for each direct treatment comparison and 
outcome, we will assess the possibility of reporting bias 
by visually examining the asymmetry of funnel plots and 
Egger’s regression test.25 We will explore the potential 
small-study effects in the network using a comparison-ad-
justed funnel plot.31
Methods for direct treatment comparisons
To supplement NMA, direct estimates will be reported and 
estimated using pairwise meta-analysis. Pairwise meta-anal-
yses for direct treatment comparisons (at least two RCTs) 
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of primary and secondary outcomes will be performed 
using the random-effects model (Review Manager V.5.3 
Nordic Cochrane Centre, The Cochrane Collaboration). 
We chose to use the random-effects model as it accounts 
for the differences between populations included in 
the different trials.25 Effect estimates and 95% CI will be 
calculated for our outcomes. We will report dichotomous 
variables as percentages while continuous variables will be 
reported as mean ±SD deviation or median (IQR).
Assessment of heterogeneity
We will qualitatively assess extent of heterogeneity by 
comparing the study population characteristics, interven-
tions and outcome of included trials within each pairwise 
comparison. To assess extent of methodological hetero-
geneity, we will qualitatively compare risk of bias within 
each pairwise comparison. We will assess the statistical 
heterogeneity within each pairwise comparison by using 
the I2 index.37 Furthermore, if considerable heteroge-
neity is found, we will attempt to explain heterogeneity 
in a subgroup analysis or metaregression, when possible. 
We will assume a common heterogeneity variance (τ2 esti-
mated using restricted maximum likelihood approach, 
across the different comparisons in the network)38–40 as 
the treatments of interest are of the same nature, in which 
the inhibition of clotting factors is essential for treatment 
to be efficacious.41
subgroup analysis and metaregression
We will prespecify the following study-level effect modifiers 
as potential sources of heterogeneity and inconsistency: 
CABG type (on/off pump), concomitant antifibrinolytic 
therapy and timing of drug initiation. Based on available 
data, we will perform subgroup analyses or metaregres-
sion for primary outcomes.
sensitivity analysis
We will also perform sensitivity analyses of the primary 
outcomes to determine the sensitivity of results to 
changes in the original assumptions. To deal with missing 
binary data, we will use the best-worst scenario analysis. 
We will also conduct a series of sensitivity analyses by 
including only trials with a low risk of bias in all domains 
and excluding studies with less than 20% dropout, 20% 
to 50% dropout and greater than 50% dropout sepa-
rately to assess the influence of participant dropout in the 
network.
dIsCussIOn
The evidence basis around the addition of an antithrom-
botic agent to aspirin after CABG has led to different 
and divergent interpretations. Indeed, although several 
studies have shown benefits in terms of improving short-
term and long-term SVG patency, the overall literature 
has not yet been able to show a clearly beneficial clinical 
effect without the cost of an increased risk of bleeding 
complications with dual antithrombotic therapy. This 
study aims to qualitatively and quantitatively synthesise 
the available evidence of comparative efficacy and safety 
of different antithrombotic agents in patients undergoing 
CABG. We will also present the relative ranking of each 
competing treatment for our outcomes of interest. To 
the best of our knowledge, this will be the first review to 
simultaneously evaluate the relative effects of multiple 
antithrombotic agents among CABG patients using an 
NMA approach.
Our review has several strengths. We will conduct 
a comprehensive literature search to identify both 
published and unpublished studies; restriction of studies 
to RCTs; duplicate assessment of eligibility, risk of bias 
and data abstraction. Moreover, we will use GRADE to 
assess the quality of included studies. Some limitations 
are predictable. First, excluding non-English studies may 
introduce publication bias. We also expect to encounter 
a considerable range of publication dates for the studies, 
and thus, contemporaneous surgical techniques and 
treatment comparisons may not reflect the current clin-
ical practice. If the number of included studies is small, 
the ability to explore heterogeneity, conduct metare-
gression and even perform NMA could be limited. If the 
degree of clinical heterogeneity is substantial and the 
distributions of important effect modifiers across treat-
ment comparisons are not balanced, the internal validity 
may be threatened. Finally, due to the study-level nature 
of our review, the lack of individual participant data will 
preclude performing a more robust analysis to explore 
differences in patient-level covariates.
The results of this NMA will inform clinicians, patients 
and guideline developers the best available evidence on 
relative benefits of antithrombotic agents after CABG 
while considering the side effect profile. We also expect 
that our findings will significantly advance the knowledge 
around the relative ranking of antithrombotic agents, 
will fill the gaps, as well as trigger further research to 
enhance clinical decision-making and patient-important 
outcomes.
EthICs And dIssEMInAtIOn
Due to the nature of the study, there are no ethical 
concerns nor informed consent required. We will dissem-
inate the results of our systematic review and NMA 
through a peer-reviewed journal.
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